Results of the Neuroblastoma-2015 Protocol for Treating Neuroblastoma in China: Experience from Multiple Centers [post]

Yan Jin, Jie Yan, Fu Li, Lian Jiang, Jun Lu, Jianxin Li, Yunpeng Dai, Jianghua Zhan, Yanna Cao, Zhongyuan Li, Yun Liu, Daowei Wang (+3 others)
2020 unpublished
ABSTRACT Background: The collaborative efforts of the Chinese Children's Cancer Group (CCCG) have led to advances in our understanding of NB biology, a standardized classification, and stratified strategies, resulting in improved outcomes in China. We aimed to assess the NB-2015 protocol formulated by the CCCG in 2015 and evaluate the extent of the impact of autologous peripheral blood stem cell transplantation (APBSCT) . Methods: This study enrolled patients with NB between 2015 and 2018 from
more » ... 2015 and 2018 from seven medical centers in China. The clinical characteristics of one hundred sixty-one patients were reviewed, and the therapeutic effect was evaluated as the impact on survival rate. Results: The 3-year event-free survival (EFS) rates of the low-, intermediate-, and high-risk groups were 95.5%, 91.6%, 51.1%, respectively. In total, 3 out of 7 (42.8%) patients with stage 2B disease, none of whom had MYCN amplifications, relapsed. A total of 47 of the 78 patients in the high-risk group underwent external-beam radiation to the primary tumor bed (dose ranging from 18 to 36 Gy). The therapeutic effect was significantly different between patients who received radiation therapy and those who did not (3-year OS P =0.041). Within the high-risk group, The 3-year EFS rates of the patients with and without APBSCT were 72.6% and 37.1%, respectively ( P =0.008). Conclusions: This study showed that using the NB-2015 protocol achieved satisfactory results without the occurrence of fatal complications. For patients in the stage 2B group, chemotherapy should be intensified. APBSCT can effectively improve the survival rate of patients with NB, especially high-risk patients.
doi:10.21203/ fatcat:br2ystxsk5csdeuljcqjoktshu